Two States Require Industry To Pay For Ongoing Drug Take-Back Programs
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.
You may also be interested in...
CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates
OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.
NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.